2008-07-14 11:54:10 -
- Regulatory News:
Q-Med AB (STO:QMED):
Time: Thursday, July 24, 2008 at 11.30 a.m. CET. -0- To join the conference: Swedish dial in number: + 46 (0)8 505 201 10 UK dial in number: +44 (0)20 7162 0025 -0- Q-Med participants: Bengt Agerup, CEO Alexander Kotsinas, CFO Madelene Sandgren, Director Investor Relations and Corporate Communications
The press
release for Q-Med AB's half-year report will be released approximately 10.30 on July 24, 2008. -0- The slide presentation will be available at: www.q-med.com/Investors/Presentations
A recorded version of the presentation will be available for seven working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 80 32 10.
Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail:
info@q-med.com. Web: www.q-med.com.
In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(R) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
This information was brought to you by Cision
newsroom.cision.com
Queries should be addressed to:
Q-Med AB (publ)
Madelene Sandgren
Director Investor Relations and Corporate Communications
Tel: + 46 (0)70 974 90 15
